SecBot SecBot
SECBOTREPLAY Home › Report › RVMD

RVMD · Revolution Medicines announced preclinical data for RM-055, a novel…

Revolution Medicines, Inc. · PRESS-RELEASE filed Apr 21, 2026 at 17:30 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Apr 21, 2026 at 17:30 ET

Revolution Medicines announced preclinical data for RM-055, a novel oral catalytic RAS(ON) inhibitor, showing deep and durable tumor regressions in KRAS G12-mutant cancer models, including tumors resistant to prior RAS inhibitors. The data were presented at the AACR Annual Meeting on April 21, 2026.

  • Revolution Medicines disclosed preclinical data for RM-055, a new class of mutant-targeted catalytic RAS(ON) inhibitors.
  • RM-055 demonstrated robust antitumor activity in KRAS G12-mutant xenograft models of pancreatic, lung, and colorectal cancers.
  • Tumors resistant to prior RAS inhibitors responded to RM-055, suggesting potential to overcome acquired resistance.
  • The compound promotes conversion of mutant RAS(ON) to RAS(OFF), mimicking natural regulation and offering a differentiated mechanism.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access